contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


subscription-of-new-shares-in-the-right-issue-2025-exercised-by-curasight-management

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and ...

<div class="abstract">Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby&nbsp;announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the disclosure of participation by members of Curasight's Board of Directors, Executive Management and team members in the Right Issue 2025 by exercise Curasight TO subscription rights to purchase new shares in the period May 12 - May 14, 2025.</div>The following is an overview of the transactions relating to participation in the Right Issue 2025:<table cellspacing="0">	<tbody>		<tr>			<td nowrap="nowrap">Name</td>			<td>Position</td>			<td>Aggregated volume, new shares</td>			<td>Price, DKK</td>		</tr>		<tr>			<td nowrap="nowrap">			</td><td>			</td><td>			</td><td>		</td></tr>		<tr>			<td nowrap="nowrap">Kirsten Drejer </td>			<td>Chair of the Board </td>			<td>45,000</td>			<td>89,100.00</td>		</tr>		<tr>			<td nowrap="nowrap">Lars Trolle</td>			<td>Deputy chair of the Board</td>			<td>81,103</td>			<td>160,583.94</td>		</tr>		<tr>			<td nowrap="nowrap">&nbsp;Ulrich Krasilnikoff</td>			<td>CEO &amp; CFO, Board member</td>			<td>1,297,379</td>			<td>2,568,810.42</td>		</tr>		<tr>			<td nowrap="nowrap">Andreas Kjær</td>			<td>CMO &amp; CSO, Board member</td>			<td>1,262,626</td>			<td>2,499,999.48</td>		</tr>		<tr>			<td nowrap="nowrap">Jacob Madsen</td>			<td>Director CMC and co-founder</td>			<td>26,220</td>			<td>51,915.60</td>		</tr>		<tr>			<td nowrap="nowrap">Total</td>			<td>			</td><td>2,712,328</td>			<td>5,370,409.44</td>		</tr>	</tbody></table><div></div>

Subscription of new shares in the Right Issue 2025 exercised by Curasight management

Name	Position	Aggregated volume, new shares	Price, DKK

Kirsten Drejer	Chair of the Board	45,000	89,100.00
Lars Trolle	Deputy chair of the Board	81,103	160,583.94
Ulrich Krasilnikoff	CEO & CFO, Board member	1,297,379	2,568,810.42
Andreas Kjær	CMO & CSO, Board member	1,262,626	2,499,999.48
Jacob Madsen	Director CMC and co-founder	26,220	51,915.60
Total		2,712,328	5,370,409.44